SHL 0.86% $26.82 sonic healthcare limited

Ann: Half Yearly Report and Accounts, page-3

  1. 530 Posts.
    lightbulb Created with Sketch. 86
    Perhaps some disappointment around the EBITDA guidance, but the results commentary did suggest a stronger than expected NPAT in H2 2024 due to cost cutting. I guess the proof will be in the pudding. Initially I was pleased by the ex covid testing revenue growth (even accounting for acquisitions), but looking at the even stronger growth in costs, this put a bit of a dampener on it. As you said, no franking credit on dividend.


 
watchlist Created with Sketch. Add SHL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.